|Bid||29.47 x 3000|
|Ask||29.45 x 1300|
|Day's range||29.38 - 29.69|
|52-week range||28.47 - 46.97|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||11.96|
|Forward dividend & yield||2.23 (7.57%)|
|Ex-dividend date||18 Aug 2022|
|1y target est||N/A|
GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.
(Reuters) -Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip British company and a global pharma major. Brown, who has extensive experience in the health and pharmaceutical industry, will join GSK from luxury fashion brand Burberry, in April and take up the job in May.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.